Jinghai J Xu

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery
    Jing Lin
    Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton Laboratories, CT 06340, USA
    Curr Top Med Chem 3:1125-54. 2003
  2. ncbi Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential
    Jinghai J Xu
    Exploratory Medicinal Sciences, Pfizer Global Research and Development, Bldg 118W, Rm W127, Pfizer Groton Labs, Eastern Point Rd, Groton, CT 06340, USA
    Chem Biol Interact 150:115-28. 2004
  3. ncbi Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714
    Bo Feng
    Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, CT 06340
    Toxicol Sci 108:492-500. 2009
  4. ncbi Multiple effects of acetaminophen and p38 inhibitors: towards pathway toxicology
    Jinghai J Xu
    Systems Biology, Pfizer Research Technology Center, 620 Memorial Drive, Cambridge, MA 02139, United States
    FEBS Lett 582:1276-82. 2008
  5. ncbi Cellular imaging predictions of clinical drug-induced liver injury
    Jinghai J Xu
    Predictive Toxicology, Pfizer Research Technology Center, Pfizer Global Research and Development, Cambridge, Massachussetts 01239, USA
    Toxicol Sci 105:97-105. 2008
  6. ncbi Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia
    Scott D Campbell
    Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton Laboratory, Eastern Point Road, MS 8118W 131, Groton, CT 06340, USA
    Chem Biol Interact 150:179-87. 2004
  7. ncbi Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1
    Cuiping Chen
    Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, MS4044, Eastern Point Rd, Groton, CT 06340, USA
    Drug Metab Dispos 33:537-46. 2005
  8. ncbi In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone
    James A Dykens
    Drug Safety Research and Development, Pfizer, Inc, Sandwich CT139NJ, UK
    Toxicol Sci 103:335-45. 2008

Detail Information

Publications8

  1. ncbi The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery
    Jing Lin
    Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton Laboratories, CT 06340, USA
    Curr Top Med Chem 3:1125-54. 2003
    ..Fundamental concepts, key tools, reagents and experimental approaches used by the drug metabolism scientist to aid a modern project team in predicting human pharmacokinetics and assessing the "drug-like" molecule are discussed...
  2. ncbi Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential
    Jinghai J Xu
    Exploratory Medicinal Sciences, Pfizer Global Research and Development, Bldg 118W, Rm W127, Pfizer Groton Labs, Eastern Point Rd, Groton, CT 06340, USA
    Chem Biol Interact 150:115-28. 2004
    ....
  3. ncbi Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714
    Bo Feng
    Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, CT 06340
    Toxicol Sci 108:492-500. 2009
    ..This study provides likely explanations for clinically observed adverse liver effects of CP-724,714...
  4. ncbi Multiple effects of acetaminophen and p38 inhibitors: towards pathway toxicology
    Jinghai J Xu
    Systems Biology, Pfizer Research Technology Center, 620 Memorial Drive, Cambridge, MA 02139, United States
    FEBS Lett 582:1276-82. 2008
    ..The advancement of pathway toxicology will be dependent on integrated applications of techniques from basic sciences and a fundamental understanding of the interdependence of multiple biological pathways in living organisms...
  5. ncbi Cellular imaging predictions of clinical drug-induced liver injury
    Jinghai J Xu
    Predictive Toxicology, Pfizer Research Technology Center, Pfizer Global Research and Development, Cambridge, Massachussetts 01239, USA
    Toxicol Sci 105:97-105. 2008
    ..Our findings provide insight to key DILI mechanisms, and suggest a new approach in hepatotoxicity testing of pharmaceuticals...
  6. ncbi Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia
    Scott D Campbell
    Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton Laboratory, Eastern Point Road, MS 8118W 131, Groton, CT 06340, USA
    Chem Biol Interact 150:179-87. 2004
    ..Inhibition of OATPs may be an important mechanism in drug-drug and drug-endogenous substance interactions...
  7. ncbi Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1
    Cuiping Chen
    Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, MS4044, Eastern Point Rd, Groton, CT 06340, USA
    Drug Metab Dispos 33:537-46. 2005
    ....
  8. ncbi In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone
    James A Dykens
    Drug Safety Research and Development, Pfizer, Inc, Sandwich CT139NJ, UK
    Toxicol Sci 103:335-45. 2008
    ..Our results suggest that the mitochondrial impairment imposed by nefazodone is profound and likely contributes to its hepatotoxicity, especially in patients cotreated with other drugs with mitochondrial liabilities...